drugset / Trial / NCT01346826

Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)

NCT01346826

Phase 4 Completed 145 enrolled Asan Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to test the hypothesis that the accelerated infusion of infliximab is not inferior to the conventional 2 hour infusion with respect to the frequency of infusion reaction.

Timeline

Start
2011-05
Primary completion
2015-10
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Infliximab Monoclonal antibody 5 mg/kg